Asset profile
HEC53856
Small molecule
Evidence outlook · lead readout
NCT04925661 · Chronic Kidney Diseases, Renal Anemia
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04925661: The trial randomized patients against both an active comparator and placebo with blinding of the study drug, but the registry record notes the placebo comparison itself was open-label, and the primary outcome was adverse-event incidence rather than a validated clinical measure; results have not been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.